Equities research analysts at Stifel Nicolaus assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The firm set a “buy” rating and a $29.00 price target on the stock. Stifel Nicolaus’ price target indicates a potential upside of 87.70% from the company’s previous close.
Contineum Therapeutics Trading Down 1.0 %
NASDAQ CTNM opened at $15.45 on Tuesday. Contineum Therapeutics has a twelve month low of $13.90 and a twelve month high of $16.06.
Contineum Therapeutics Company Profile
Read More
- Five stocks we like better than Contineum Therapeutics
- Comparing and Trading High PE Ratio Stocks
- AMD is Down 35%. Now is the Time to Buy the Dip
- What Are Dividend Achievers? An Introduction
- Amazon Stands Tall: New Highs Are in Sight
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.